Maxim Group lifts Chimerix Inc. [CMRX] price estimate. Who else is bullish?

Chimerix Inc. [NASDAQ: CMRX] price surged by 7.87 percent to reach at $0.17. The company report on August 29, 2022 that Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


– Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years –.

– Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones -.

A sum of 36078233 shares traded at recent session while its average daily volume was at 4.82M shares. Chimerix Inc. shares reached a high of $2.68 and dropped to a low of $2.10 until finishing in the latest session at $2.33.

The one-year CMRX stock forecast points to a potential upside of 69.34. The average equity rating for CMRX stock is currently 1.60, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Chimerix Inc. [CMRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CMRX shares is $7.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CMRX stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Maxim Group have made an estimate for Chimerix Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 29, 2021. While these analysts kept the previous recommendation, Cowen raised their target price from $10 to $18. The new note on the price target was released on April 23, 2021, representing the official price target for Chimerix Inc. stock. Previously, the target price had yet another raise to $21, while Wedbush analysts kept a Outperform rating on CMRX stock.

The Average True Range (ATR) for Chimerix Inc. is set at 0.27, with the Price to Sales ratio for CMRX stock in the period of the last 12 months amounting to 368.57. The Price to Book ratio for the last quarter was 7.28, with the Price to Cash per share for the same quarter was set at 0.45.

CMRX Stock Performance Analysis:

Chimerix Inc. [CMRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.69. With this latest performance, CMRX shares gained by 6.39% in over the last four-week period, additionally sinking by -58.69% over the last 6 months – not to mention a drop of -67.41% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CMRX stock in for the last two-week period is set at 48.55, with the RSI for the last a single of trading hit 46.65, and the three-weeks RSI is set at 49.00 for Chimerix Inc. [CMRX]. The present Moving Average for the last 50 days of trading for this stock 2.25, while it was recorded at 2.33 for the last single week of trading, and 4.29 for the last 200 days.

Insight into Chimerix Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Chimerix Inc. [CMRX] shares currently have an operating margin of -4573.52 and a Gross Margin at +76.35. Chimerix Inc.’s Net Margin is presently recorded at -8753.71.

Return on Equity for this stock declined to -244.64, with Return on Assets sitting at -187.02.

Chimerix Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.20.

Chimerix Inc. [CMRX] Insider Position Details

There are presently around $119 million, or 63.90% of CMRX stock, in the hands of institutional investors. The top three institutional holders of CMRX stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 7,084,604, which is approximately 47.596% of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 5,778,626 shares of the stock with an approximate value of $13.46 million in CMRX stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $12.28 million in CMRX stock with ownership of nearly 90.547% of the company’s market capitalization.

Positions in Chimerix Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 65 institutional holders increased their position in Chimerix Inc. [NASDAQ:CMRX] by around 16,581,070 shares. Additionally, 63 investors decreased positions by around 17,922,935 shares, while 19 investors held positions by with 16,571,478 shares. The mentioned changes placed institutional holdings at 51,075,483 shares, according to the latest SEC report filing. CMRX stock had 25 new institutional investments in for a total of 8,564,252 shares, while 27 institutional investors sold positions of 7,543,707 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here